Technology

AI is transforming content reviews to focus on relevant use, not just generation.

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Ted Sweetser discusses how the technology is expanding the amount of content that can be created.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease patients.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Marcel Botha, CEO of 10XBeta, identifies the most significant technological innovations in medical device manufacturing that will be crucial for future pandemic preparedness and supply chain stability.

Matthew Yelovich, partner at Cleary Gottlieb, discusses his transition in late-2024 from working as a federal prosecutor to a role at Cleary Gottlieb, as well as how he sees the intersection of technology and law evolving in the Bay Area.

Matthew Yelovich, partner at Cleary Gottlieb, discusses some of the broader implications for corporate governance and accountability the Theranos case highlights.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

If used properly, AI can be a game-changer for drug development.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Jennifer Kyle, CEO and founder of Condor, explores how improving financial management directly impacts drug pricing.

Jennifer Kyle, CEO and founder of Condor, discusses the inspiration behind creating a financial cloud platform specifically for biopharma R&D.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, discusses ethical considerations surrounding AI use in medication access and how the industry can ensure that these technologies are used responsibly and equitably.

Kimberley Chiang, vice president of biopharma commercial solutions at CoverMyMeds, addresses patient and prescriber expectations for digital health tools.

In an era where business-critical information is exchanged instantly, unsecured communication channels are a significant risk.

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Making early commercial data and analytics decisions for launch cen future-proof their data management.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship with patients and new technology.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores ways that digital health platforms can assist pharma companies seeking to maintain accessibility and manage cost pressures.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.

James Foster, CEO and co-founder of Virax Biolabs, discusses how AI and machine-learning algorithms are changing the ways that companies approach their launch strategies.

The benefits for brand teams in bolstering their rapid-response capability.